Prognostic Value of Combined Lactate Dehydrogenase, C-Reactive Protein, Cancer Antigen 153 and Cancer Antigen 125 in Metastatic Breast Cancer

Overview

Journal Cancer Control

Specialty Oncology

Date 2022 Jan 6

PMID 34989251

Citations 5

Authors

Yu-Yuan Ma

Han Wang

Wei-Dong Zhao

Yi-Fan Li

Jing-Jing Wang

Xing-Yu Chen

Yue-Qing Huang

Wen-Jie Wang

Ying Wang

Shi-Chang Sun

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer (BC), especially metastatic BC, is one of the most lethal diseases in women. CA 125 and CA 15-3 are commonly used indicators for diagnosis and prognosis of BC. Some serological indicators, such as lactate dehydrogenase (LDH) and C-reactive protein (CRP), can also be used to assess the prognosis and progression in BC.

Methods: Univariate Cox regression analysis and LASSO regression analysis were performed to identify prognostic factors and build prognostic models. We distributed the patients into 2 groups based on the median risk score, analyzed prognosis by Kaplan-Meier curve, and screened independent prognostic factors by multivariate Cox regression analysis.

Result: We identified 4 indicators-LDH, CRP, CA 15-3, and CA 125-related to the prognosis in BC and established a prognostic model. The high LDH group showed worse overall survival (OS) than low LDH group ( = .017; hazard ratio (HR), 1.528; 95% confidence interval (CI), 1.055-2.215). The high CRP group showed worse OS than low CRP group ( = .004; HR, 1.666; 95% CI, 1.143-2.429). The high CA153 group showed worse OS than low CA 15-3 group (P=.011; HR, 1.563; 95% CI, 1.075-2.274). The high CA 125 group showed worse OS than low CA 125 group ( = .021; HR, 1.499; 95% CI, 1.031-2.181). The area under the curve for risk score was .824, Ki-67 was .628, age was .511, and grade was .545. Risk score was found to be an independent prognostic factor using multivariate Cox regression analysis.

Conclusion: We successfully established an optimization model by combining 4 prognosis-related indicators to assess the prognosis in patients with metastatic BC.

Citing Articles

Monitoring of postoperative neutrophil-to-lymphocyte ratio, D-dimer, and CA153 in: Diagnostic value for recurrent and metastatic breast cancer.

Ren Z, Yang J, Liang J, Xu Y, Lu G, Han Y Front Surg. 2023; 9:927491.

PMID: 36684341 PMC: 9853451. DOI: 10.3389/fsurg.2022.927491.

The Prognostic Value of Preoperative Serum D-dimer Levels After Surgical Resection of Thymic Epithelial Tumors.

Huang Y, Liu X, Liang S, Hu Y, Ma G Cancer Control. 2022; 29:10732748221129108.

PMID: 36373938 PMC: 9666872. DOI: 10.1177/10732748221129108.

The correlation between neutrophil-to-lymphocyte ratio, carcinoembryonic antigen, and carbohydrate antigen 153 levels with chemotherapy-related cognitive impairment in early-stage breast cancer patients.

Yu S, Zhao J, Wang M, Cheng G, Li W, Tang L Front Med (Lausanne). 2022; 9:945433.

PMID: 36091709 PMC: 9453200. DOI: 10.3389/fmed.2022.945433.

Prognostic Value of Preclinical Markers after Radiotherapy of Metastatic Spinal Cord Compression-An Additional Analysis of Patients from Two Prospective Trials.

Rades D, Cacicedo J, Lomidze D, Al-Salool A, Segedin B, Groselj B Cancers (Basel). 2022; 14(10).

PMID: 35626151 PMC: 9139528. DOI: 10.3390/cancers14102547.

Prognostic biomarkers of malignant patients with pleural effusion: a systematic review and meta-analysis.

Peng P, Yang Y, Du J, Zhai K, Shi H Cancer Cell Int. 2022; 22(1):99.

PMID: 35209915 PMC: 8876446. DOI: 10.1186/s12935-022-02518-w.

References

Tagliafico A, Bignotti B, Rossi F, Matos J, Calabrese M, Valdora F . Breast cancer Ki-67 expression prediction by digital breast tomosynthesis radiomics features. Eur Radiol Exp. 2019; 3(1):36. PMC: 6694353. DOI: 10.1186/s41747-019-0117-2. View

Pelizzari G, Basile D, Zago S, Lisanti C, Bartoletti M, Bortot L . Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker. Cancers (Basel). 2019; 11(9). PMC: 6770929. DOI: 10.3390/cancers11091243. View

Wulaningsih W, Holmberg L, Garmo H, Malmstrom H, Lambe M, Hammar N . Prediagnostic serum inflammatory markers in relation to breast cancer risk, severity at diagnosis and survival in breast cancer patients. Carcinogenesis. 2015; 36(10):1121-8. DOI: 10.1093/carcin/bgv096. View

Aman N, Doukoure B, Koffi K, Koui B, Traore Z, Kouyate M . Immunohistochemical Evaluation of Ki-67 and Comparison with Clinicopathologic Factors in Breast Carcinomas. Asian Pac J Cancer Prev. 2019; 20(1):73-79. PMC: 6485584. DOI: 10.31557/APJCP.2019.20.1.73. View

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

Li H, Chen K, Su F, Song E, Gong C . Preoperative CA 15-3 levels predict the prognosis of nonmetastatic luminal A breast cancer. J Surg Res. 2014; 189(1):48-56. DOI: 10.1016/j.jss.2014.02.048. View

Touvier M, Fezeu L, Ahluwalia N, Julia C, Charnaux N, Sutton A . Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am J Epidemiol. 2012; 177(1):3-13. PMC: 3529490. DOI: 10.1093/aje/kws359. View

Di Gioia D, Blankenburg I, Nagel D, Heinemann V, Stieber P . Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3. Clin Chim Acta. 2016; 461:1-7. DOI: 10.1016/j.cca.2016.07.014. View

Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Matsuoka Y . Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer. Breast Cancer. 2003; 10(3):220-7. DOI: 10.1007/BF02966721. View

10.

Song X, Liang B, Wang C, Shi S . Clinical value of color Doppler ultrasound combined with serum CA153, CEA and TSGF detection in the diagnosis of breast cancer. Exp Ther Med. 2020; 20(2):1822-1828. PMC: 7388249. DOI: 10.3892/etm.2020.8868. View

11.

Tibshirani R . The lasso method for variable selection in the Cox model. Stat Med. 1997; 16(4):385-95. DOI: 10.1002/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3. View

12.

Villasenor A, Flatt S, Marinac C, Natarajan L, Pierce J, Patterson R . Postdiagnosis C-reactive protein and breast cancer survivorship: findings from the WHEL study. Cancer Epidemiol Biomarkers Prev. 2013; 23(1):189-99. PMC: 3911892. DOI: 10.1158/1055-9965.EPI-13-0852. View

13.

Gong T, Liu J, Jiang J, Zhai Y, Wu C, Ma C . The role of lactate deshydrogenase levels on non-small cell lung cancer prognosis: a meta-analysis. Cell Mol Biol (Noisy-le-grand). 2019; 65(1):89-93. View

14.

Gallo M, Sapio L, Spina A, Naviglio D, Calogero A, Naviglio S . Lactic dehydrogenase and cancer: an overview. Front Biosci (Landmark Ed). 2015; 20(8):1234-49. DOI: 10.2741/4368. View

15.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

16.

Ullah M . Breast Cancer: Current Perspectives on the Disease Status. Adv Exp Med Biol. 2019; 1152:51-64. DOI: 10.1007/978-3-030-20301-6_4. View

17.

Li L, Gao Q, Xu G, Shi B, Ma X, Liu H . Postoperative recurrence analysis of breast cancer patients based on clinical serum markers using discriminant methods. Cancer Biomark. 2017; 19(4):403-409. DOI: 10.3233/CBM-160322. View

18.

Li J, Liu L, Feng Z, Wang X, Huang Y, Dai H . Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study. Breast Cancer. 2020; 27(4):621-630. DOI: 10.1007/s12282-020-01058-3. View

19.

Liu D, Wang D, Wu C, Zhang L, Mei Q, Hu G . Prognostic significance of serum lactate dehydrogenase in patients with breast cancer: a meta-analysis. Cancer Manag Res. 2019; 11:3611-3619. PMC: 6497911. DOI: 10.2147/CMAR.S199260. View

20.

Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J . Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015; 5(10):2929-43. PMC: 4656721. View